anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a preparation method and clinical application of a poliosis-treating medicament. A precursor of the medicament is a basic medium containing 15 percent human AB serum, and the basic medium consists of 15 milliliters of human AB serum, 85 milliliters of low-glucose DMEM culture medium, 0.24 gram of Hepes, 0.2 gram of sodium bicarbonate and 0.03 gram of L-glutamine. The preparation method comprises the steps of culturing first and second dermal papilla cells by use of the basic medium, collecting culture supernatant of the first and second dermal papilla cells as a dermal papilla cell conditional medium and preparing the collected dermal papilla cell conditional medium into freeze-dried powder. The medicament prepared by the method has obvious therapeutic effects of treating poliosis. Both the cells and the culture serum used in the medicament have no antigenicity to human bodies and cause no anaphylaxis to the human bodies. In addition, because the medicament is injected subcutaneously, the effective utilization degree of the medicament is greatly raised.
PCT No. PCT/EP95/02343 Sec. 371 Date Nov. 27, 1996 Sec. 102(e) Date Nov. 27, 1996 PCT Filed Jun. 16, 1995 PCT Pub. No. WO95/35302 PCT Pub. Date Dec. 28, 1995Compounds of formula (I),    <IMAGE>  (I)  wherein R is a biphenyl group optionally substituted, by one or more substituents, the same or different selected among halogen atoms, hydroxy groups, alkoxy, alkyl thioalkyl or alkoxycarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety, C1-C3 alkyl groups containing one or more fluorine atoms, carboxy groups, nitro groups, amino or aminocarbonyl groups, acylamino groups, aminosulphonyl groups, momo- or di-alkylamino groups having from 1 to 6 carbon atoms in the alkyl moiety, mono- or di-alkylamino-carbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety; R1 is a hydrogen atom, a straight or branched C1-C6 alkyl group or an arylalkyl group having from 1 to 6 carbon atoms in the alkyl moiety wherein the aryl is a phenyl, a biphenyl, a napthyl or a 5 or 6 membered aromatic heterocycle with one or two heteroatoms selected among nitrogen, oxygen and sulphur, optionally substituted with one or more substituents, the same or different, selected among halogen atoms, hydroxy groups, alkoxy, alkyl, thioalkyl or alkoxycarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety, C1-C3 alkyl groups containing one or more fluorine atoms, carboxy groups, nitro groups, amino or aminocarbonyl groups, acylamino groups, aminosulphonyl groups, mono- or di-alkylamino groups having from 1 to 6 carbon atoms in the alkyl moiety, mono- or di-alkylaminocarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety; R2 is a straight or branched C1-C6 alkyl group, optionally containing one or more fluorine atoms or one or more -NH- groups, an arylalkyl, an arylcarbonylaminoalkyl, an arylalkylcarbonylaminoalkyl or an arylaminocarbonylalkyl group having from 1 to 6 carbon atoms and optionally one or more -NH- groups in the alkyl moiety, the aryl being optionally substituted by one or more substituents, the same or different, selected among halogen atoms, hydroxy groups, alkoxy, alkyl, thioalkyl or alkoxycarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety, C1-C3 alkyl groups containing one or more fluorine atoms, carboxy groups, nitro groups, amino or aminocarbonyl groups, acylamino groups, aminosulphonyl groups, mono-or di-alkylamino groups having from 1 to 6 carbon atoms in the alkyl moiety, mono- or di-alkylaminocarbonyl groups having from 1 to 6 carbon atoms in the alkyl moiety; m is 0 or 1; X is a hydrogen or fluorine atom; the carbon atom marked with an asterisk is an asymmetric carbon atom; and their pharmaceutically acceptable salts, are described. The compounds of formula (I) are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.
1458354 Hair preparations UNILEVER Ltd 17 Jan 1974 [17 Jan 1973] 2513/73 Heading A5B A hair control preparation for holding the hair in a desired configuration comprises a solution of 2-20% by weight of a volatile normally solid material (i.e. a material which is solid at 20‹C yet which is volatile at that temperature) and a perfume. The preparation may also comprise less than 0.5 parts by weight of a film-forming resin for each part by weight of the volatile material. The preparation may be presented in the form of an aerosol hairspray and, for that purpose, may include a liquefied gaseous propellant (e.g. trichlorofluoromethane or dichlorodifluoromethane). The volatile material may be camphor, camphene, feuchyl alcohol, propionamide, menthol, thymol, methyl-2-naphthylketone, hexachlorethane, benzophenone or acetamide and this material may be dissolved in a volatile organic solvent such as methylene chloride, ethanol, isopropanol or 2-methoxyethanol. The ethanol may be used in the form of industrial methylated spirit and may contain an additional denaturant (e.g. sucrose octaacetate). Various copolymers of vinylacetate or methyl acrylate or methyl vinyl ether are specified as film-forming resins.
Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
Cohort 2 (also in-person) will experience this same meditation as Cohort 1 concurrently through headphones (in a space separate from Cohort 1). Participants in all cohorts will be asked to attend one of the weekly sessions offered twice a week for the entirety of the 8 weeks for at least 1 hour. Participants will also be given access and asked to listen to virtual music-backed mindfulness guided meditations to listen to between in- person sessions.
A system that monitors particle motion behavior for point-of-care diagnostics is described. The system can include a sample testing unit configured to house a sample. The sample testing unit can include a plurality of motor structures configured for self-propulsion based on a presence or an absence of a target analyte in the sample and a plurality of beads configured to experience a motion behavior based on the self-propulsion of the plurality of motor structures. Each of the plurality of motor structures can include a catalytic motor-like micro/nanoparticle; and an attached functional material specific for the target analyte attached to the catalytic motor-like particle. The optical recording unit can include an optical arrangement configured to detect the motion behavior of the beads in the sample testing unit. The motion behavior can be indicative of the presence or the absence of the target analyte.
PURPOSE:To provide the titled cosmetic composed of a pigment having specific diameter, sodium alginate, etc. and sodium ethylene-diaminetetraacetate, etc., having low viscosity and excellent lining and coating capability, and extrudable easily from the pen without causing clogging of the pen. CONSTITUTION:The objective cosmetic is composed of (A) a pigment having particle diameter of <=1mu, (B) sodium alginate, carboxymethylcellulose sodium salt, sodium polyacrylate, sodium, ammonium or N-alkanolamine salt, etc. of shellac or their mixture having strong property of protective colloid and effective as a dispersant to prevent the precipitation of the pigment, and (C) sodium, trisodium or disodium salt of ethylenediaminetetraacetic acid as an insolubilizing agent of a porous thermoplastic resin. The viscosity of the cosmetic is 1.5-50cp. The liquid cosmetic is filled in a pen-type cosmetic container such as eyeliner having a pen especially made of a urethane resin.
NEW MATERIAL:A pyridylketoxime ether derivative expressed by formula 1 [Ar is aromatic or heterocyclic; X is -(CH2)m-, -(CH2)m-Y-, -CH2-(CH=CH)n-(m is 1-5; n is 1-2; Y is O or S); R is phenyl, naphthyl, cycloalkyl or heterocyclic]. EXAMPLE:O-Benzyl-phenyl-2-pyridylketoxime. USE:A medicine having calmodulins antagonism. A remedy for ischemic disease and various kind of diseases accompanied thereby. PREPARATION:For example, pyridyl ketone expressed by formula IV is reacted with hydroxyamine to give pyridylketoxime expressed by formula II, which is then subjected to condensation reaction with a halide derivative expressed by formula III to provide the compound expressed by formula I. The compound expressed by formula I is as necessary converted to salt thereof.
The invention discloses a composition for resisting fatigue and improving immunity and a preparation method and application thereof, belonging to the field of anti-fatigue health care products. The composition for resisting fatigue and improving immunity comprises the following components: coenzyme Q10 and grape seed extract. According to the invention, coenzyme Q10 is combined with various natural antioxidant substances, the anti-fatigue activity of different compositions is investigated, and finally, the composition consisting of coenzyme Q10 and grape seed extract is found to have the most remarkable anti-fatigue activity. The invention further determines the optimal dosage ratio of the coenzyme Q10 and the grape seed extract through a dosage screening experiment. Animal experiments and biochemical index measurement results show that the composition has extremely obvious functions of resisting fatigue activity and enhancing immunity. The composition can be used for preparing medicines, health-care products, beverages or foods and the like for resisting fatigue and improving immunity, and has good safety and no side effect.
Provided is a recombinant viral vector that expresses a NKG2D activating ligand, such as a UL-16 binding protein. When introduced into a cancer cell, the vector can cause expression of the NKG2D activating ligand, thereby overcoming repression of NK-mediated (or other effector cell, e.g., macrophage) cytotoxicity and causing effector cell-mediated death of the cancer cell. Expression of the NKG2D activating ligand can be controlled by a miRNA present in greater concentration in noncancerous cells than in cancer cells, which can permit selective expression of the ligand in cancer cells and reduced cytotoxicity toward noncancerous cells. The vector can cause expression of an oncolytic factor. When formulated into a pharmaceutical composition and administered to a patient, the vector can be used to treat cancer. The cancer can be a glioma, such as glioblastoma including one with an isocitrate dehydrogenase (IDH) mutation. The vector can be a herpes simplex virus vector, among others.
This article begins with an overview of twin research in Brazil, initiated by the University of São Paulo Panel of Twins. I met with many new research collaborators and students while on a fall 2023 four-city lecture tour in that country. A meeting with a world-famous surgeon who recently separated craniopagus conjoined twin pairs is also described. This overview is followed by summaries of twin research on binge eating, twins' physical outcomes linked to different diets, working conditions and sickness absence in Swedish Twins and facial morphology differences in monozygotic twins. The final section of this article provides a sampling of human interest stories with important implications. They include a Michigan family forced to adopt their own twins, ethical issues surrounding the hiring of a surrogate to bear twins; twin survivors of the Israel-Hamas war, a twin pregnancy with a double uterus, and three twin pairs on the same women's soccer team.
PCT No. PCT/US97/00224 Sec. 371 Date Jan. 12, 1998 Sec. 102(e) Date Jan. 12, 1998 PCT Filed Jan. 3, 1997 PCT Pub. No. WO97/25068 PCT Pub. Date Jul. 17, 1997This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and/or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.
The invention relates to biotechnology, immunology and virology. There is created an expression vector containing the genome of recombinant human adenovirus serotype 26, wherein the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 (variant 1). Therein, the sequence SEQ ID NO: 5 was used as a parental sequence of human adenovirus serotype 26. Further, there is created an expression vector, containing the genome of recombinant simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 (variant 2). Therein, the sequence SEQ ID NO: 6 was used as a parental sequence of simian adenovirus serotype 25. Furthermore, there is created an there is created containing the genome of recombinant human adenovirus serotype 5, wherein the E1 and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 (variant 3). Therein, the sequence SEQ ID NO: 7 was used as a parental sequence of human adenovirus serotype 5. There is also developed a method of utilization of the developed expression vector for creating an immunobiological agent for the induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2.
The present invention provides a fluid exchange cell culture technique an d tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for t he production of TRC populations with greater tissue repair and anti- inflam matory capabilities. Embodiments of the present invention include a post-cul ture process for cultured cells that preferably includes the steps of: a was h process for removing unwanted residual culture components, a volume reduct ion process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamb er by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be conc entrated to a final volume for the intended use. In such embodiments, the fi nal composition is a substantially purified and concentrated cell mixture su spended in a physiologic solution suitable for immediate use in humans witho ut further washing, volume reduction, or processing. Embodiments are also ap plicable to harvesting (and/or washing) particles within a liquid or solutio n within a chamber.
ETHNOPHARMACOLOGICAL RELEVANCE: Ferns form an important part of the human diet. Young fern fiddleheads are mostly consumed as vegetables, while the rhizomes are often extracted for starch. These edible ferns are also often employed in traditional medicine, where all parts of the plant are used, mostly to prepare extracts. These extracts are applied either externally as lotions and baths or internally as potions, decoctions and teas. Ailments traditionally treated with ferns include coughs, colds, fevers, pain, burns and wounds, asthma, rheumatism, diarrhoea, or skin diseases (eczema, rashes, itching, leprosy).
AIM OF THE REVIEW: This review aims to compile the worldwide knowledge on the traditional medicinal uses of edible fern species correlating to reported biological activities and isolated bioactive compounds.
MATERIALS AND METHODS: The articles and books published on edible fern species were searched through the online databases Web of Science, Pubmed and Google Scholar, with critical evaluation of the hits. The time period up to the end of 2022 was included.
RESULTS: First, the edible fern species were identified based on the literature data. A total of 90 fern species were identified that are eaten around the world and are also used in traditional medicine. Ailments treated are often associated with inflammation or bacterial infection. However, only the most common and well-known fern species, were investigated for their biological activity. The most studied species are Blechnum orientale L., Cibotium barometz (L.) J. Sm., Diplazium esculentum (Retz.) Sw., Marsilea minuta L., Osmunda japonica Thunb., Polypodium vulgare L., and Stenochlaena palustris (Burm.) Bedd. Most of the fern extracts have been studied for their antioxidant, anti-inflammatory and antimicrobial activities. Not surprisingly, antioxidant capacity has been the most studied, with results reported for 28 edible fern species. Ferns have been found to be very rich sources of flavonoids, polyphenols, polyunsaturated fatty acids, carotenoids, terpenoids and steroids and most of these compounds are remarkable free radical scavengers responsible for the outstanding antioxidant capacity of fern extracts. As far as clinical trials are concerned, extracts from only three edible fern species have been evaluated.
CONCLUSIONS: The extracts of edible fern species exert antioxidant anti-inflammatory and related biological activities, which is consistent with their traditional medicinal use in the treatment of wounds, burns, colds, coughs, skin diseases and intestinal diseases. However, studies to prove pharmacological activities are scarce, and require chemical-biological standardization. Furthermore, correct botanical classification needs to be included in publications to simplify data acquisition. Finally, more in-depth phytochemical studies, allowing the linking of traditional use to pharmacological relevance are needed to be done in a standardized way.
This group will receive a weight-maintaining diet without soda. All 50% of carbohydrates will originate from sources other than corn and sugar cane.
Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
We plan on enrolling 25 subjects from each of the four sites. After signing a consent form, subjects will be screened and asked to have a physical and specific safety labs done to make sure they can safely participate in the study. After the screening visit, subjects will be randomly, like a flip of a coin, placed into one of two groups. One group will get the study drug, Geodon. The other group will get placebo, a sugar pill. Neither the doctor nor subject will know in which group the subject has been placed.

Subjects will see the doctor once a week for 6 weeks. During each visit, we will check and treat any side effects. We will ask questions about mood and go through a number of rating scales and assessments that will look at mood and symptoms. Subjects will also fill out questionnaires at each visit to assess their moods and see how the study is going. At the final visit, subjects will have the same physical exam and lab tests done as in the initial visit.
A novel medicament for the treatment of estrogen-deficient disease states is disclosed. Said medicament is a combination preparation comprising an ERss-selective estrogen and an ER alpha -selective antiestrogen or SERM (Selective Estrogen Receptor Modulator). The antiestrogen or SERM which is a component of the combination preparation is preferably selective for the periphery. The preparation is suitable for an organ-specific estrogen therapy and has clear advantages over conventional therapies. Due to the combination of ER alpha -selective SERM and ERss-estrogen the preparation permits a complete protection against bone loss caused by estrogen deficiency. The components of the medicament also have a synergistic effect with respect to the inhibition of inflammation inducing genes, in particular in inflammatory disorders such as atherosclerosis and arthritis, or neurodegenerative diseases such as Alzheimers and multiple sclerosis. Furthermore, positive effects on cognition and mood may be expected. The protective estrogen-like effects are achieved, with no expectation of proliferation effects on breasts or uterus.
Sixty participants diagnosed with acquired pneumonia '30 women, 30 men; selected from chest department of Kasr Alaini Intensive Care Unit (ICU) at Cairo University. They were randomly allocated into equal groups; Group A received respiratory training via incentive spirometer, and traditional chest physiotherapy; and Group B received respiratory training via Breather, and traditional chest physiotherapy. both received 3 session daily/2 weeks. Diaphragmatic excursion, Respiratory Distress Observation Scale, and ICU discharge were assessed pre and post treatment.

Careful recruitment of participants based on the study criteria by both ICU resident and PT consultant. Identified inclusive criteria include conscious both genders aged 30- 40 years old with BMI ranged from 25 to5 29.9 Kg/m2 had an acquired pneumonia with a mild hypoxemia (O2 saturation was 90 - 95%). Aware participants whom cooperated through accurate understand and perform instructions. Excluding patients through identified inclusive criteria that if they had a history of any malignant tumors, hearing impairment or mental disorder, auto-immune diseases, a history of any surgical transplantation, unstable hemodynamics, rib fracture, a history of neuromuscular disease, spinal injuries, or BMI \> 30 Kg/m2. Also, patients receiving mechanical ventilation, or whom require MV, but contraindicated for rehabilitation i.e., pulmonary emboli were excluded.
PROBLEM TO BE SOLVED: To obtain a new compound useful as an anionic surface-active agent applicable to detergents for dishes and vegetables, shampoos, body shampoos, hand soaps, house detergents and oral cavity products of e.g. dentifrice or a mouth-rinsing agent. SOLUTION: This compound is shown by the formula R1O(G)n-(A)mOSO3M [R1 is a 6-30C higher alkyl or alkenyl; G is shown by formula I or II (B is H or SO3M); A is a 4-8C polyhydric alcohol residue; (n) is an average condensation molar number of 1 to 10; (m) an average condensation molar number of 1 to 5; and M is H or a salt-formable cationic ion], e.g. lauryl glyceryl ether erythritol sodium sulfate. A compound of the formula may be produced by subjecting a glycidyl ether and polyhydric alcohol to condensation reaction in the presence of e.g. basic catalyst for obtaining a glyceryl etherified polyhydric alcohol as a raw material, by reacting the resultant product with a sulfating reagent and by neutralizing it with an alkaline aqueous solution.
Amputees patients also conservative protocol will undergo physical therapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
Each participant of the experimental group will undergo an initial cognitive screening (pre-training) and, in addition to their standard of care, they will have 20 additional sessions of neuropsychological standard sessions. Post-treatment cognitive screening will be completed at the end of the program, then 3-4 and 6-12 months later.